Characterization of hepatitis B virus inhibition by novel 2′-fluoro-2′,3′-unsaturated beta-D- and L-nucleosides

Antiviral Chemistry and Chemotherapy

Volumn 16, Issue 3, 2005, Pages 183-192

  Pai, S Balakrishna ^a   Pai, Rekha B ^b   Xie, Meng Yu ^b   Beker, Tolunay ^b   Shi, Junxing ^b   Tharnish, Philip M ^b   Chu, Chung K ^c   Schinazi, Raymond F ^a,b  

^a ATLANTA VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

Antiviral agents; HBV; Nucleoside analogues

Indexed keywords

BETA 2' FLUORO 2',3' DIDEOXY 2',3' DIDEHYDRO 5 FLUOROCYTIDINE; BETA 2' FLUORO 2',3' DIDEOXY 2',3' DIDEHYDROCYTIDINE; CYTIDINE DERIVATIVE; DEOXYCYTIDINE TRIPHOSPHATE; FIALURIDINE; LAMIVUDINE; MITOCHONDRIAL DNA; NUCLEOSIDE DERIVATIVE; PHOSPHORUS 32; RNA POLYMERASE II; UNCLASSIFIED DRUG; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; CELL FUNCTION; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DNA SYNTHESIS INHIBITION; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; ENANTIOMER; ENZYME INHIBITION; HEMATOPOIETIC STEM CELL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; MONKEY; NONHUMAN; PRIORITY JOURNAL; SUBSTITUTION REACTION; VIRUS CORE; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS TRANSCRIPTION;

EID: 27244452854     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020501600304     Document Type: Article

References (38)

1. Aloman C & Wands JR (2003) Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy? Hepatology 38:1584-1587.
2. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A & Locarnini S (2003) Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292-297.
3. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P & Locarnini S (1997) Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. Journal of Hepatology 26:1148-1153.
4. Bartholomeusz A, Furman P & Locarnini S (2003) Novel approaches in the management of chronic HBV infection. In Frontiers in Viral Hepatitis; pp. 225-243. Edited by RF Schinazi, J-P Sommadossi & CM Rice. New York: Elsevier.
5. Beach JW, Jeong LS, Alves AJ, Pohl D, Kim HO, Chang C-N, Doong S-L, Schinazi RF, Cheng Y-C & Chu CK (1992) Synthesis of enantiomerically pure (2′R,5′S)-(-)-1-[2-(hydroxymethyl)oxathiolan-5-yl]cytosine as a potent antiviral agent against hepatitis B virus (HBV) and human immunodeficiency virus (HIV). Journal of Organic Chemistry 57:2217-2219.
6. Beasley RP, Hwang LY, Lin CC & Chien CS (1981) Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 2:1129-1133.
7. Ben-Ari Z, Zemel R, Kazetsker A, Fraser G & Tur-Kaspa R (1999) Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation. American Journal of Gastroenterology 94:663-667.
8. Blumberg BS (2002) Hepatitis B: the hunt for a killer virus. Princeton, NJ, USA: Princeton University Press.
9. Chen H, Pai SB, Hurwitz SJ, Chu CK, Glazkova Y, McClure HM, Feitelson M & Schinazi RF (2003) Antiviral activity and pharmacokinetics of 1-(2,3-dideoxy-2-fluoro-beta-1,-glyceropent-2-enofuranosyl) cytosine. Antimicrobial Agents & Chemotherapy 47:1922-1928.
10. Chiou HL, Lee TS, Kuo J, Mau YC & Ho MS (1997) Altered anti-genicity of 'a' determinant variants of hepatitis B virus. Journal of General Virology 78:2639-2645.
11. Faraj A, Fowler DA, Bridges EG & Sommadossi JP (1994) Effects of 2′,3′-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis. Antimicrobial Agents & Chemotherapy 38:924-930.
12. Faraj A, Schinazi RF, Xie MY, Gosselin G, Perigaud C, Imbach JL & Sommadossi JP (1996) Selective protection of toxicity of 2′,3′- dideoxypyrimidine nucleoside analogs by beta-D-uridine in human granulocyte-macrophage progenitor cells. Antiviral Research 29:261-267.
13. Hoofnagle JH & di Bisceglie AM (1997) The treatment of chronic viral hepatitis. New England Journal of Medicine 336:347-356.
14. Korba BE, Cote P, Hornbuckle W, Tennant BC & Gerin JL (2000) Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 31:1165-1175.
15. Koshida R, Cox S, Harmenberg J, Gilljam G & Wahren B (1989) Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 33:2083-2088.
16. Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeger C & King RW (1997) Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrobial Agents & Chemotherapy 41:1715-1720.
17. Ladner SK, Miller TJ, Otto MJ & King RW (1998) The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antiviral Chemistry & Chemotherapy 9:65-72.
18. Lee K, Choi Y, Gullen E, Schlueter-Wirtz S, Schinazi RF, Cheng Y-C & Chu CK (1999) Synthesis and anti-HIV and anti-HBV activities of 2′-fluoro-2′,3′-unsaturated L-nucleosides. Journal of Medicinal Chemistry 42:1320-1328.
19. Martin JA, Bushnell DJ, Duncan IB, Dunsdon SJ, Hall MJ, Machin PJ, Merrett JH, Parkes KE, Roberts NA, Thomas GJ, Galpin SA & Kinchington D (1990) Synthesis and antiviral activity of monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1). Journal of Medicinal Chemistry 33:2137-2145.
20. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, De Man RA & Thomas HC (1997) Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 113:1258-1263.
21. Pai SB, Liu SH, Zhu YL, Chu CK & Cheng YC (1996) Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-beta-L- arabinofuranosyl uracil. Antimicrobial Agents & Chemotherapy 40:380-386.
22. Pai SB, Pai RB & Schinazi RF (2003) Treatment modalities for hepatitis B viral infection and resistance to antiviral therapy. Panminerva Medica 45:165-173.
23. Pan-Zhou XR, Cui L, Zhou XJ, Sommadossi JP & Darley-Usmar VM (2000) Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrobial Agents & Chemotherapy 44:496-503.
24. Pas SD, Fries E, De Man RA, Osterhaus AD & Niesters HG (2000) Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. Journal of Clinical Microbiology 38:2897-2901.
25. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann HL, Samuel D, Zeuzem S, Lilly L, Rendina M, Villeneuve JP, Lama N, James C, Wulfsohn MS, Namini H, Westland C, Xiong S, Choy GS, Van Doren S, Fry J & Brosgart CL (2003) Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38:1419-1427.
26. Schinazi RF (1991) Combined chemotherapeutic modalities for viral infections: rationale and clinical potential. In Synergism and Antagonism in Chemotherapy, pp. 110-181. Edited by TC Chou & DC Rideout. Orlando, FL, USA: Academic Press.
27. Schinazi RF, Chu CK, Peck A, McMillan A, Mathis R, Cannon D, Jeong LS, Beach JW, Choi WB, Yeola S & Liotta DC (1992) Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrobial Agents & Chemotherapy 36:672-676.
28. Seeger C, Baldwin B, Hornbuckle WE, Yeager AE, Tennant BC, Cote P, Ferrell L, Ganem D & Varmus HE (1991) Woodchuck hepatitis virus is a more efficient oncogenic agent than ground squirrel hepatitis virus in a common host. Journal of Virology 65:1673-1679.
29. Sells MA, Zelent AZ, Shvartsman M & Acs G (1988) Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. Journal of Virology 62:2836-2844.
30. Shi J, McAtee JJ, Schlueter Wirtz S, Tharnish P, Juodawlkis A, Liotta DC & Schinazi RF (1999) Synthesis and biological evaluation of 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (D4FC) analogues: discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase. Journal of Medicinal Chemistry 42:859-867.
31. Sommadossi JP & Carlisle R (1987) Toxicity of 3′-azido- 3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrobial Agents & Chemotherapy 31:452-454.
32. Sterzycki RZ, Ghazzouli I, Brankovan V, Martin JC & Mansuri MM (1990) Synthesis and anti-HIV activity of several 2′-fluoro-containing pyrimidine nucleosides. Journal of Medicinal Chemistry 33:2150-2157.
33. Stuyver LJ, Lostia S, Adams M, Mathew JS, Pai SB, Grier J, Tharnish PM, Choi Y, Chong Y, Choo H, Chu CK, Otto MJ & Schinazi RF (2002) Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy- 2′,3′-didehydrocytidine analogues. Antimicrobial Agents & Chemotherapy 46:3854-3860.
34. Szmuness W (1978) Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Progress in Medical Virology 24:40-69.
35. Tennant BC (2001) Animal models of hepadnavirus-associated hepatocellular carcinoma. Clinical Liver Diseases 5:43-68.
36. Villa E, Boarino V, Grottola A, Gelmini R & Lama NG (2003) Predominance of pre-S1 mutated hepatitis B virus in a patient following treatment with adefovir dipivoxil. Liver Transplantation 9:188-190.
37. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS & Heathcote J (1993) Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Annals of Internal Medicine 119:312-323.
38. Zollner B, Schafer P, Feucht HH, Schroter M, Petersen J & Laufs R (2001) Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. Journal of Medical Virology 65:659-663.